| Ident. | Authors (with country if any) | Title |
|---|
| 000F96 |
Penny A. Rudd [Australie] ; Jane Wilson [Australie] ; Joy Gardner [Australie] ; Thibaut Larcher [France] ; Candice Babarit [France] ; Thuy T. Le [Australie] ; Itaru Anraku [Australie] ; Yutaro Kumagai [Japon] ; Yueh-Ming Loo [États-Unis] ; Michael Jr Gale [États-Unis] ; Shizuo Akira [Japon] ; Alexander A. Khromykh [Australie] ; Andreas Suhrbier [Australie] | Interferon Response Factors 3 and 7 Protect against Chikungunya Virus Hemorrhagic Fever and Shock |
| 001F03 |
Erin L. Lousberg [Australie] ; Cara K. Fraser [Australie] ; Michael G. Tovey [France] ; Kerrilyn R. Diener [Australie] ; John D. Hayball [Australie] | Type I Interferons Mediate the Innate Cytokine Response to Recombinant Fowlpox Virus but Not the Induction of Plasmacytoid Dendritic Cell-Dependent Adaptive Immunity |
| 002066 |
Naoto Ito [Japon] ; Gregory W. Moseley [Australie] ; Danielle Blondel [France] ; Kenta Shimizu [Japon] ; Caitlin L. Rowe [Australie] ; Yuki Ito [Japon] ; Tatsunori Masatani [Japon] ; Keisuke Nakagawa [Japon] ; David A. Jans [Australie] ; Makoto Sugiyama [Japon] | Role of Interferon Antagonist Activity of Rabies Virus Phosphoprotein in Viral Pathogenicity |
| 002202 |
Laure Campillo-Gimenez [France] ; Mireille Laforge [France] ; Michèle Fay [France] ; Audrey Brussel [France] ; Marie-Christine Cumont [France] ; Valérie Monceaux [France] ; Ousmane Diop [Sénégal] ; Yves Levy [France] ; Bruno Hurtrel [France] ; John Zaunders [Australie] ; Jacques Corbeil [Canada] ; Carole Elbim [France] ; Jérôme Estaquier [France] | Nonpathogenesis of Simian Immunodeficiency Virus Infection Is Associated with Reduced Inflammation and Recruitment of Plasmacytoid Dendritic Cells to Lymph Nodes, Not to Lack of an Interferon Type I Response, during the Acute Phase |
| 002286 |
Timothy P. Hughes [Australie] ; Andreas Hochhaus [Allemagne] ; Susan Branford [Australie] ; Martin C. Müller [Allemagne] ; Jaspal S. Kaeda [Portugal] ; Letizia Foroni [Royaume-Uni] ; Brian J. Druker [États-Unis] ; François Guilhot [France] ; Richard A. Larson [États-Unis] ; Stephen G. O'Brien [Royaume-Uni] ; Marc S. Rudoltz [États-Unis] ; Manisha Mone [États-Unis] ; Elisabeth Wehrle [Suisse] ; Vijay Modur [États-Unis] ; John M. Goldman [Royaume-Uni] ; Jerald P. Radich [États-Unis] | Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) |
| 002F58 |
Violaine Amaud [France] ; JUN LI [République populaire de Chine] ; YUANYUAN WANG [République populaire de Chine] ; XIAO FU [République populaire de Chine] ; SHI MENGZHI [République populaire de Chine] ; XINSONG LUO [République populaire de Chine] ; XUNYA HOU [République populaire de Chine] ; Helia Dessein [France] ; ZHOU JIE [République populaire de Chine] ; Xin-Ling Yu [République populaire de Chine] ; HONGBIN HE [France, République populaire de Chine] ; Donald P. Mcmanus [Australie] ; YUESHENG LI [République populaire de Chine, Australie] ; Alain Dessein [France] | Regulatory Role of Interleukin-10 and Interferon-y in Severe Hepatic Central and Peripheral Fibrosis in Humans Infected with Schistosoma japonicum |
| 003228 |
B. Melichar [République tchèque] ; P. Koralewski [Pologne] ; A. Ravaud [France] ; A. Pluzanska [Pologne] ; S. Bracarda [Italie] ; C. Szczylik [Pologne] ; C. Chevreau [France] ; M. Filipek [Pologne] ; R. Delva [France] ; E. Sevin [France] ; S. Negrier [France] ; J. Mckendrick [Australie] ; A. Santoro [Italie] ; P. Pisa [Suisse] ; B. Escudier [France] | First-line bevacizumab combined with reduced dose interferon-a2a is active in patients with metastatic renal cell carcinoma |
| 003422 |
Stefan Zeuzem [Allemagne] ; Eric M. Yoshida [Canada] ; Yves Benhamou [France] ; Stephen Pianko [Australie] ; Vincent G. Bain [Canada] ; Daniel Shouval [Israël] ; Robert Flisiak [Pologne] ; Vratislav Rehak [Roumanie] ; Mircea Grigorescu [République tchèque] ; Kelly Kaita [Canada] ; Patrick W. Cronin [États-Unis] ; Erik Pulkstenis [États-Unis] ; G. Mani Subramanian [États-Unis] ; John G. Mchutchison [États-Unis] | Albinterferon Alfa-2b Dosed Every Two or Four Weeks in Interferon-Naïve Patients With Genotype 1 Chronic Hepatitis C |
| 003A55 |
Anna S. Lok [États-Unis] ; Fabien Zoulim [France] ; Stephen Locarnini [Australie] ; Angeline Bartholomeusz [Australie] ; Marc G. Ghany [États-Unis] ; Jean-Michel Pawlotsky [France] ; Yun-Fan Liaw [Taïwan] ; Masashi Mizokami [Japon] ; Carla Kuiken [États-Unis] | Antiviral drug-resistant HBV : Standardization of nomenclature and assays and recommendations for management |
| 004F42 |
Stephen G. O'Brien [Royaume-Uni, France, États-Unis, Suisse, Italie, Espagne, Pays-Bas, Allemagne, Australie, Suède] ; Francois Guilhot ; Richard A. Larson ; Insa Gathmann ; Michele Baccarani ; Francisco Cervantes ; Jan J. Cornelissen ; Thomas Fischer ; Andreas Hochhaus ; Timothy Hughes ; Klaus Lechner ; Johan L. Nielsen ; Philippe Rousselot ; Josy Reiffers ; Giuseppe Saglio ; John Shepherd ; Bengt Simonsson ; Alois Gratwohl ; John M. Goldman ; Hagop Kantarjian ; Kerry Taylor ; Gregor Verhoef ; Ann E. Bolton ; Renaud Capdeville ; Brian J. Druker | Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia |
| 006857 |
G. C. Farrell [Australie] | Two years versus six months of interferon therapy for chronic hepatitis C |
